Alnylam defends against Tekmira complaint.

Alnylam defends against Tekmira complaint, files answer and counterclaim Alnylam Pharmaceuticals, Inc. , a respected RNAi therapeutics organization, has filed a remedy and counterclaim to a complaint filed by Tekmira Pharmaceuticals Corporation in the Business Litigation Program of the Massachusetts Better Court. Our focus remains on the advancement of RNAi therapeutics to sufferers and execution on our clinical programs.These P values were modified for the comparison of the zidovudine-alone group with the two multidrug organizations. Adjusted P values for all possible comparisons had been 0.07 for the zidovudine-alone group versus the two-drug group, 0.09 for the zidovudine-alone group versus the three-drug group, and 0.80 for the two-drug group versus the three-drug group. Loss and Mortality to Follow-up Forty-three infants died, with similar mortality in the three groupings . No deaths were considered to be related to the study drugs.